CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Coherus Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.96−0.03 (-3.16%)
Close on Oct 19, 2026
- Market cap
- $148.42M
- P/E (TTM)
- 0.7
- Dividend yield
- –
Fundamental chart
Pick a measure to chart its full history
$42.17MFY2025, +26.9% a year since FY2012